|
1
|
Marley AR and Nan H: Epidemiology of
colorectal cancer. Int J Mol Epidemiol Genet. 7:105–114.
2016.PubMed/NCBI
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chiang CJ, Lo WC, Yang YW, You SL, Chen CJ
and Lai MS: Incidence and survival of adult cancer patients in
Taiwan, 2002–2012. J Formos Med Assoc. 115:1076–1088. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siegel RL, Miller KD, Fedewa SA, Ahnen DJ,
Meester RGS, Barzi A and Jemal A: Colorectal cancer statistics,
2017. CA Cancer J Clin. 67:177–193. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Arnold M, Sierra MS, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global patterns and trends in
colorectal cancer incidence and mortality. Gut. 66:683–691. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Moreno CC, Mittal PK, Sullivan PS,
Rutherford R, Staley CA, Cardona K, Hawk NN, Dixon WT, Kitajima HD,
Kang J, et al: Colorectal cancer initial diagnosis: Screening
colonoscopy, diagnostic colonoscopy, or emergent surgery, and tumor
stage and size at initial presentation. Clin Colorectal Cancer.
15:67–73. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Holch JW, Ricard I, Stintzing S, Modest DP
and Heinemann V: The relevance of primary tumour location in
patients with metastatic colorectal cancer: A meta-analysis of
first-line clinical trials. Eur J Cancer. 70:87–98. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Peng Y and Croce CM: The role of MicroRNAs
in human cancer. Signal Transduct Target Ther. 1:150042016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Svoronos AA, Engelman DM and Slack FJ:
OncomiR or tumor suppressor? The duplicity of microRNAs in cancer.
Cancer Res. 76:3666–3670. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fabris L, Ceder Y, Chinnaiyan AM, Jenster
GW, Sorensen KD, Tomlins S, Visakorpi T and Calin GA: The potential
of microRNAs as prostate cancer biomarkers. Eur Urol. 70:312–322.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mohammadi A, Mansoori B and Baradaran B:
The role of microRNAs in colorectal cancer. Biomed Pharmacother.
84:705–713. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xu B, Tao T, Wang Y, Fang F, Huang Y, Chen
S, Zhu W and Chen M: hsa-miR-135a-1 inhibits prostate cancer cell
growth and migration by targeting EGFR. Tumour Biol.
37:14141–14151. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang X, Gao F, Zhou L, Wang H, Shi G and
Tan X: UCA1 regulates the growth and metastasis of pancreatic
cancer by sponging miR-135a. Oncol Res. 25:1529–1541. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wu Q, Shi M, Meng W, Wang Y, Hui P and Ma
J: Long noncoding RNA FOXD3-AS1 promotes colon adenocarcinoma
progression and functions as a competing endogenous RNA to regulate
SIRT1 by sponging miR-135a-5p. J Cell Physiol. 234:21889–21902.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vafadari B, Salamian A and Kaczmarek L:
MMP-9 in translation: From molecule to brain physiology, pathology,
and therapy. J Neurochem. 139 (Suppl 2):S91–S114. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kehlet SN, Harling H, Jørgensen LN,
Karsdal MA and Willumsen N: Effect of MMP-13 degraded SPARC on type
I collagen and its biomarker potential in colorectal cancer. J Clin
Oncol. 36 (Suppl 4):S7172018. View Article : Google Scholar
|
|
17
|
Yamada T, Oshima T, Yoshihara K, Tamura S,
Kanazawa A, Inagaki D, Yamamoto N, Sato T, Fujii S, Numata K, et
al: Overexpression of MMP-13 gene in colorectal cancer with liver
metastasis. Anticancer Res. 30:2693–2699. 2010.PubMed/NCBI
|
|
18
|
Rath T, Roderfeld M, Graf J, Wagner S,
Vehr AK, Dietrich C, Geier A and Roeb E: Enhanced expression of
MMP-7 and MMP-13 in inflammatory bowel disease: A precancerous
potential? Inflamm Bowel Dis. 12:1025–1035. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Aran V, Victorino AP, Thuler LC and
Ferreira CG: Colorectal cancer: Epidemiology, disease mechanisms
and interventions to reduce onset and mortality. Clin Colorectal
Cancer. 15:195–203. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Levin TR, Corley DA, Jensen CD,
Schottinger JE, Quinn VP, Zauber AG, Lee JK, Zhao WK, Udaltsova N,
Ghai NR, et al: Effects of organized colorectal cancer screening on
cancer incidence and mortality in a large community-based
population. Gastroenterology. 155:1383–1391.e5. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Drewes JL, Housseau F and Sears CL:
Sporadic colorectal cancer: Microbial contributors to disease
prevention, development and therapy. Br J Cancer. 115:273–280.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tribollet V, Barenton B, Kroiss A, Vincent
S, Zhang L, Forcet C, Cerutti C, Périan S, Allioli N, Samarut J and
Vanacker JM: miR-135a inhibits the invasion of cancer cells via
suppression of ERRα. PLoS One. 11:e01564452016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yan HQ, Zhang D, Shi YY, You X, Shi L, Li
Q and Gao FG: Ataxia-telangiectasia mutated activation mediates
tumor necrosis factor-alpha induced MMP-13 up-regulation and
metastasis in lung cancer cells. Oncotarget. 7:62070–62083. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xu H and Wen Q: Downregulation of miR-135a
predicts poor prognosis in acute myeloid leukemia and regulates
leukemia progression via modulating HOXA10 expression. Mol Med Rep.
18:1134–1140. 2018.PubMed/NCBI
|
|
26
|
Zhou Y, Li S, Li J, Wang D and Li Q:
Effect of microRNA-135a on cell proliferation, migration, invasion,
apoptosis and tumor angiogenesis through the IGF-1/PI3K/Akt
signaling pathway in non-small cell lung cancer. Cell Physiol
Biochem. 42:1431–1446. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lin L, He Y, Xi BL, Zheng HC, Chen Q, Li
J, Hu Y, Ye MH, Chen P and Qu Y: miR-135a suppresses calcification
in senescent VSMCs by regulating KLF4/STAT3 pathway. Curr Vasc
Pharmacol. 14:211–218. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Agarwal E, Robb CM, Smith LM, Brattain MG,
Wang J, Black JD and Chowdhury S: Role of Akt2 in regulation of
metastasis suppressor 1 expression and colorectal cancer
metastasis. Oncogene. 36:3104–3118. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cheng Z, Liu F, Zhang H, Li X, Li Y, Li J,
Liu F, Cao Y, Cao L and Li F: miR-135a inhibits tumor metastasis
and angiogenesis by targeting FAK pathway. Oncotarget.
8:31153–31168. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jabłońska-Trypuć A, Matejczyk M and
Rosochacki S: Matrix metalloproteinases (MMPs), the main
extracellular matrix (ECM) enzymes in collagen degradation, as a
target for anticancer drugs. J Enzyme Inhib Med Chem. 31 (Suppl
1):S177–S183. 2016. View Article : Google Scholar
|
|
31
|
Louka ML and Ramzy MM: Involvement of
fibroblast-specific protein 1 (S100A4) and matrix
metalloproteinase-13 (MMP-13) in CCl4-induced reversible liver
fibrosis. Gene. 579:29–33. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zeng L, Rong XF, Li RH and Wu XY: Icariin
inhibits MMP-1, MMP-3 and MMP-13 expression through MAPK pathways
in IL-1β-stimulated SW1353 chondrosarcoma cells. Mol Med Rep.
15:2853–2858. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sheibani S, Mahmoudian RA, Abbaszadegan
MR, Chamani J, Memar B and Gholamin M: Expression analysis of
matrix metalloproteinase-13 in human gastric cancer in the presence
of Helicobacter Pylori infection. Cancer Biomark. 18:349–356. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
von Felden J, Heim D, Schulze K, Krech T,
Ewald F, Nashan B, Lohse AW and Wege H: High expression of micro
RNA-135A in hepatocellular carcinoma is associated with recurrence
within 12 months after resection. BMC Cancer. 17:602017. View Article : Google Scholar : PubMed/NCBI
|
